Skip to search formSkip to main contentSkip to account menu

emtricitabine

Known as: 4-Amino-5-fluoro-1-((2R,5S)-2-hydroxymethyl-[1,3]oxathiolan-5-yl)-1H-pyrimidin-2-one, Emtricitabinum, (-)-cis-4-amino-5-Fluoro-1-(2-hydroxymethyl-1,3-oxathiolan-5-yl)-(1H)-pyrimidin-2-one 
A synthetic fluoro derivative of thiacytidine with potent antiviral activity. Emtricitabine is phosphorylated to form emtricitabine 5'-triphosphate… 
National Institutes of Health

Related topics

Related topics

28 relations

Broader (3)

Anti-HIV AgentsAntiviral AgentsReverse Transcriptase Inhibitors

Narrower (8)

AtriplaBW 524W91CompleraCoviracil
Emtricitabine:Susc:Pt:Isolate:OrdQn:PhenotypingHIV InfectionsIn BloodLamivudine or Emtricitabine:Susc:Pt:Isolate:OrdQn:Genotyping

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Review
2018
Review
2018
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2018 Recommendations of the International Antiviral Society–USA Panel
Importance Antiretroviral therapy (ART) is the cornerstone of prevention and management of HIV infection. Objective To evaluate… 
Highly Cited
2017
Highly Cited
2017
Efficacy, safety, and effect on sexual behaviour of on-demand pre-exposure prophylaxis for HIV in men who have sex with men: an observational cohort study.
Highly Cited
2016
Highly Cited
2016
A Translational Pharmacology Approach to Predicting Outcomes of Preexposure Prophylaxis Against HIV in Men and Women Using Tenofovir Disoproxil Fumarate With or Without Emtricitabine.
BACKGROUND A novel translational pharmacology investigation was conducted by combining an in vitro efficacy target with mucosal… 
Highly Cited
2015
Highly Cited
2015
Ledipasvir and Sofosbuvir for HCV in Patients Coinfected with HIV-1.
BACKGROUND Effective treatment for hepatitis C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1… 
Highly Cited
2015
Highly Cited
2015
HIV pre-exposure prophylaxis in transgender women: A subgroup analysis of the iPrEx trial
Highly Cited
2013
Highly Cited
2013
Final 192‐week efficacy and safety of once‐daily darunavir/ritonavir compared with lopinavir/ritonavir in HIV‐1‐infected treatment‐naïve patients in the ARTEMIS trial
This paper presents the final analysis of once‐daily darunavir/ritonavir (DRV/r) vs. lopinavir/ritonavir (LPV/r) in treatment‐na… 
Highly Cited
2011
Highly Cited
2011
Penetration of Tenofovir and Emtricitabine in Mucosal Tissues: Implications for Prevention of HIV-1 Transmission
Antiretroviral drugs are found at different concentrations in human cervical, vaginal, and rectal mucosal tissues with… 
Highly Cited
2010
Highly Cited
2010
Once-Daily Atazanavir/Ritonavir Compared With Twice-Daily Lopinavir/Ritonavir, Each in Combination With Tenofovir and Emtricitabine, for Management of Antiretroviral-Naive HIV-1–Infected Patients: 96…
Background:Once-daily atazanavir/ritonavir demonstrated similar antiviral efficacy to twice-daily lopinavir/ritonavir over 48… 
Review
2009
Review
2009
Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.
BACKGROUND The use of fixed-dose combination nucleoside reverse-transcriptase inhibitors (NRTIs) with a nonnucleoside reverse… 
Highly Cited
2009
Highly Cited
2009
Glucuronidation of the Antiretroviral Drug Efavirenz by UGT2B7 and an in Vitro Investigation of Drug-Drug Interaction with Zidovudine
The non-nucleoside reverse transcriptase inhibitor efavirenz (EFV) is directly conjugated by the UDP-glucuronosyltransferase (UGT… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)